Erythropoietin and Parkinson's disease: Suggested mechanisms and therapeutic implications

Medical Hypotheses

Volumn 70, Issue 1, 2008, Pages 211-212

  Genc, Kursad ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON; NEUROTROPHIC FACTOR; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG TARGETING; HUMAN; LETTER; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE;

EID: 36448944725     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.010     Document Type: Letter

References (16)

1. Aykan S., Egrilmez M., Genc S., and Guner G. Erythropoietin upregulates NF-E2 related factor 2 expression in astroglial cells in vitro. FEBS J 273 Suppl. 1 (2006) 237
2. Bailey D.M., Robach P., Thomsen J.J., and Lundby C. Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke?. Stroke 37 (2006) 2453
3. Burton N.C., Kensler T.W., and Guilarte T.R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 27 (2006) 1094-1100
4. de Lau L.M., and Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006) 525-535
5. Ehrenreich H., Hinze-Selch D., Stawicki S., Aust C., Knolle-Veentjer S., Wilms S., et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12 (2007) 206-220
6. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
7. Genc S., Kuralay F., Genc K., Akhisaroglu M., Fadiloglu S., Yorukoglu K., et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 298 (2001) 139-141
8. Genc S., Koroglu T.F., and Genc K. Erythropoietin and the nervous system. Brain Res 1000 (2004) 19-31
9. Genc S., Egrilmez M.Y., and Genc K. Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage. Med Hypotheses 67 (2006) 424
10. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
11. Martinez-Estrada O.M., Rodriguez-Millan E., Gonzalez-De Vicente E., Reina M., Vilaro S., and Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 18 (2003) 2538-2544
12. Park M.H., Lee S.M., Lee J.W., Son D.J., Moon D.C., Yoon D.Y., et al. ERK-mediated production of neurotrophic factors by astrocytes promotes neuronal stem cell differentiation by erythropoietin. Biochem Biophys Res Commun 339 (2006) 1021-1028
13. Signore A.P., Weng Z., Hastings T., Van Laar A.D., Liang Q., Lee Y.J., et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 96 (2006) 428-443
14. van Muiswinkel F.L., and Kuiperij H.B. The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 4 (2005) 267-281
15. Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 2007 Mar 14; [Epub ahead of print].
16. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873